Metabolic adverse events associated with systemic corticosteroid therapy—a systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Objectives: To assess the risk of new-onset or worsening hyperglycaemia, hypertension, weight gain and hyperlipidaemia with systemic corticosteroid therapy (CST) as reported in published randomised control trial (RCT) studies. Data sources: Literature search using MEDLINE, EMBASE, Cochrane library, Web of Science and Scopus Study eligibility criteria: Published articles on results of RCT with a systemic CST arm with numerical data presented on adverse effect (AE). Participants and interventions: Reports of hyperglycaemia, hypertension, weight gain and hyperlipidaemia associated with systemic CST in patients or healthy volunteer’s ≥17 years of age. Study appraisal methods: Risk of bias tool, assessment at the level of AE and key study characteristics. Results: A total of 5446 articles were screened to include 118 studies with 152 systemic CST arms (total participants=17 113 among which 8569 participants treated with CST). Pooled prevalence of hyperglycaemia in the CST arms within the studies was 10% (95% CI 7% to 14%), with the highest prevalence in respiratory illnesses at 22% (95% CI 9% to 35%). Pooled prevalence of severe hyperglycaemia, hypertension, weight gain and hyperlipidaemia within the corticosteroid arms was 5% (95% CI 2% to 9%), 6% (95% CI 4% to 8%), 13% (95% CI 8% to 18%), 8% (95% CI 4% to 17%), respectively. CST was significantly associated hyperglycaemia, hypertension and weight gain as noted in double-blinded placebo-controlled parallel-arms studies: OR of 2.13 (95% CI 1.66 to 2.72), 1.68 (95% CI 0.96 to 2.95) and 5.20 (95% CI 2.10 to 12.90), respectively. Intravenous therapy posed higher risk than oral therapy: OR of 2.39 (95% CI 1.16 to 4.91). Limitations: There was significant heterogeneity in the AE definitions and quality of AE reporting in the primary studies and patient populations in the studies. The impact of cumulative dose effect on incidental AE could not be calculated. Conclusions and implications of key findings: Systemic CST use is associated with increased risk of metabolic AEs, which differs for each disease group and route of administration. PROSPERO registration number: CRD42020161270.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Suurmond, R., van Rhee, H., & Hak, T. (2017) · Research Synthesis Methods · doi:10.1002/jrsm.1260 · Cited by 881
Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis
Broersen, L. H. A., Pereira, A. M., Jørgensen, J. O. L., & Dekkers, O. M. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1218 · Cited by 456
Systematic reviews of adverse effects: framework for a structured approach
Loke, Y. K., Price, D., Herxheimer, A., & the Cochrane Adverse Effects Methods Group (2007) · BMC Medical Research Methodology · doi:10.1186/1471-2288-7-32 · Cited by 253
Risk of Diabetes Associated With Prescribed Glucocorticoids in a Large Population
Gulliford, M. C., Charlton, J., & Latinovic, R. (2006) · Diabetes Care · doi:10.2337/dc06-1499 · Cited by 211
Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD
Burt, M. G., Roberts, G. W., Aguilar-Loza, N. R., Frith, P., & Stranks, S. N. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2729 · Cited by 203
van Raalte, D. H., Brands, M., van der Zijl, N. J., Muskiet, M. H., Pouwels, P. J. W., Ackermans, M. T., Sauerwein, H. P., Serlie, M. J., & Diamant, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2174-9 · Cited by 109
Burt, M. G., Drake, S. M., Aguilar‐Loza, N. R., Esterman, A., Stranks, S. N., & Roberts, G. W. (2015) · Internal Medicine Journal · doi:10.1111/imj.12680 · Cited by 38
Tatalovic, M., Lehmann, R., Cheetham, M., Nowak, A., Battegay, E., & Rampini, S. K. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-028914 · Cited by 27
Cited by
9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Glucocorticoid-Induced Hyperglycemia: A Neglected Problem
Cho, J.-H., & Suh, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1951 · Cited by 63
Jain, A. B., & Lai, V. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01628-0 · Cited by 32
“A systematic review reported an even higher risk of hyperglycemia with intravenous steroids compared to oral steroids, with an odds ratio of 2.39 (95% CI 1.16–4.91) [14].”
BackgroundInfluentialKatz, A., Shulkin, A., Housni, A., Roy‐Fleming, A., Rabasa‐Lhoret, R., Yale, J., Tsoukas, M. A., Peters, T. M., & Brazeau, A. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70465 · Cited by 3
“3 – 7 GC-induced hyperglycaemia is mediated by several mechanisms, including increased hepatic gluconeogenesis, decreased peripheral glucose uptake, and reduced insulin sensitivity, all of which can complicate glycaemic management in susceptible populations, 8,9 such as in individuals with diabetes.”
Metadata
- Authors
- Kulkarni, S., Durham, H., Glover, L., Ather, O., Phillips, V., Nemes, S., Cousens, L., Blomgran, P., & Ambery, P.
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2022-12
- Volume
- 12
- Issue
- 12
- Pages
- e061476
- ISSN
- 2044-6055 (ISSN-L)
- OpenAlex
- W4312075457
- Cited by
- 69
- References
- 9
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic adverse events associated with systemic corticosteroid therapy—a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1136/bmjopen-2022-061476
- The paper
- Kulkarni, S., Durham, H., Glover, L., Ather, O., Phillips, V., Nemes, S., Cousens, L., Blomgran, P., & Ambery, P. (2022). Metabolic adverse events associated with systemic corticosteroid therapy—a systematic review and meta-analysis. BMJ Open. https://doi.org/10.1136/bmjopen-2022-061476
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.